ARK Invest's position in VCYT, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 2,339,271 | $57.6M | 0.79% | #37 |
| ARKG | 1,841,279 | $45.4M | 2.30% | #16 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-05 | ARKK | Buy | Added | 348,829 | $8.4M |
| 2026-11-05 | ARKG | Buy | Added | 166,192 | $4.0M |
| 2026-10-07 | ARKG | Buy | Added | 4,913 | $212K |
| 2026-10-06 | ARKG | Buy | Added | 389,509 | $17.4M |
| 2026-10-05 | ARKG | Buy | Added | 115,472 | $5.5M |
| 2026-10-01 | ARKK | Buy | Added | 159,376 | $7.0M |
| 2026-09-30 | ARKK | Buy | Added | 76,392 | $3.5M |
| 2026-09-29 | ARKK | Buy | Added | 119,416 | $5.5M |
| 2026-09-23 | ARKG | Buy | Added | 20,908 | $916K |
| 2026-09-22 | ARKG | Buy | Added | 12,583 | $546K |
| 2026-09-21 | ARKG | Buy | Added | 74,878 | $3.1M |
| 2026-09-04 | ARKK | Buy | Added | 22,144 | $942K |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer…
See VCYT's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open VCYT on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.